AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03422523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg
Description: intravenous drip
Study NCT03422523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin 100 MG
Description: intravenous drip
Study NCT03422523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 100 MG
Description: intravenous drip
Study NCT03133052 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: internet-based adaptive cognitive control training program
Description: The cognitive training will be an internet-based adaptive cognitive control training program, specific training paradigms include Flanker, 1-back, 2-back. To maintain task difficulty, the tasks will be grouped based on the task difficulty. Furthermore, each task will have various difficulty levels.
Study NCT03133052 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo program
Description: For the control group, a fixed, primary difficulty level program for all participants is set.
Study NCT04190641 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ambu aScope 4 Cysto and aView Urologia
Description: Visualization of the urethra and the bladder
Study NCT02124369 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abraxane
Description: 125mg/m2, IV, on days 1,8 \& 15 of each 28 day cycle, up to 6 cycles.
Study NCT02124369 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: 1000mg/m2, IV, on days 1,8 \& 15 of a 28 day cycle, up to 6 cycles.
Study NCT00497094 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: carotid artery stenting
Description: Using retrograde transfemoral access an overview aortic angiogram is established. A stiff wire is then placed in the external carotid or distal common carotid artery to introduce a long hydrophilic sheath into the common carotid artery. The stenosis is then crossed with a Filter wire. For stent implantation Monorail Carotid Wallstents or the Monorail Nitinol Stent of Boston Scientific are used. Road map or overlay technique with a magnification of 20 to 28 inch is used to localize the stenosis during the procedure. Finally a control angiogram is performed to ensure correct placement of the stent. After successful completion of the procedure, the arterial access site is closed using a standard closure device.
Study NCT02700061 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic occupational therapy
Description: Robotic Occupational Therapy three times a week for twelve weeks.
Study NCT02700061 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induced Constraint Therapy - ICT
Description: Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
Study NCT03762811 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NanoFUSE® Bioactive Matrix
Description: NanoFUSE® is placed into bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure.
Study NCT02798627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS2359
Description: NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.
Study NCT02798627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pills identical in appearance to the NS2359 will be provided
Study NCT02426346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral weight control
Description: Prescription of diet \& physical activity and behavioral strategies for weight control
Study NCT02426346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight control
Description: Prescription of diet \& physical activity and behavioral strategies for weight control
Study NCT02426346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based physical activity
Description: Teens exercise for 60 minutes with their group
Study NCT02426346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based incentives
Description: Adolescents earn reinforcements within group
Study NCT02426346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent-based incentives
Description: Adolescents earn reinforcements from their parents (outside of group)
Study NCT04684251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coil embolisation of hemorrhoidal arteries.
Description: Coil embolisation of hemorrhoidal arteries as previously described.
Study NCT00946101 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]
Description: 0.5 mL: (intranasal sprayer)
Study NCT00946101 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer
Study NCT03660800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP101 Capsules
Description: Calcifediol Extended-Release Capsules
Study NCT02404935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT02404935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI and cetuximab
Study NCT02404935 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FOLFIRI and cetuximab
Study NCT02084992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expanded technology disease management
Description: Tablet computers loaded with a web-based disease management program will be given to patients for the duration of the study.
Study NCT02084992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephonic disease management
Study NCT01677897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Adding Metformin to Abiraterone in case of PSA-Progression
Study NCT00520325 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous recombinant human mannose binding lectin
Description: Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
Study NCT02873143 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04053660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Mechanical non-surgical treatment were performed
Study NCT01763697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: taste acuity assessment
Description: Quantitative measurement of for tasting detection and recognition thresholds, magnitude of perception and hedonic response.
Study NCT01763697 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: taste acuity assessment
Description: Quantitative measurement of for tasting detection and recognition thresholds, magnitude of perception and hedonic response.
Study NCT01763697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recorded meal
Study NCT01763697 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Recorded meal
Study NCT04643210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: F2F MoB EI
Description: The MoB F2F EI will comprise a total of 12 educational F2F sessions. Each session will have a duration of 1.5 hours and the maximum number of participants in the groups will be 12 patients.~The intervention group will receive the MoB F2F EI on group or personal form according to the participant's choice. The implementation methodology of the MoB F2F EI will include videos and power point presentations, as well as interactive learning methods such as role-playing, empowerment exercises, live discussions.
Study NCT04643210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MoB DP
Description: This is a technology-based intervention, which regards access to a dfigital platform, the MoB DP. The structure of the Digital platform has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.
Study NCT04643210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MoB DP
Description: This is a technology-based intervention, which regards access to a dfigital platform, the MoB DP. The structure of the Digital platform has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.
Study NCT02671708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin（IDA）
Description: Idarubicin was administered at 15mg/m2/day on days -12 and -10.
Study NCT02671708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
Study NCT02671708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
Study NCT02671708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study NCT02671708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study NCT00000817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Description: 75 mg oral tablet taken daily
Study NCT00000817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride placebo
Description: Oral placebo tablet taken daily
Study NCT00000817 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Point acupuncture
Description: Standardized or alternate acupuncture procedure
Study NCT03428984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: EXAPREL 266 mg in 20 mL
Study NCT00313014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
Study NCT00313014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
Study NCT00313014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Immediate-Release
Description: Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).
Study NCT02254135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR - rising dose
Study NCT02254135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01466712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium + formoterol/beclometasone
Description: Tiotropium 18 µg/dose once daily (handihaler device) + formoterol, fumarate 6µg + beclometasone, dipropionate 100µg / dose (Pressurised inhaler): 2 puffs bid, for one month.
Study NCT01466712 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: tiotropium + placebo
Description: Tiotropium 18 µg/dose once daily (handihaler device) + placebo (Pressurised inhaler): 2 puffs bid, for one month.
Study NCT01703143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser ablation
Description: Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
Study NCT03081117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin, intranasal
Description: Regular insulin administered by specialized, non-commercial intranasal drug delivery device
Study NCT03081117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, intranasal
Description: Saline solution administered by specialized, non-commercial intranasal drug delivery device
Study NCT04216056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frailty intervention program
Description: There will be 2 sessions per week for 12 weeks. Each session includes 1 hour exercise (including 5-10 minute warm-up and cool-down routine, 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body, and 20-30 minutes aerobic exercises); and 1 hour game training using computer video games, board games and card games. Nutrition education will be given to the subjects based on their weight status. The 1st level of nutrition information (healthy eating tips for frailty prevention and management) will be given to all subjects on regular basis during the 12-week study period via short videos, text messages or Whatsapp reminders. On top of the 1st level nutrition information, 3 nutrition heath talks (1-1.5 hours per talk) about weight management will be given to those with BMI >=25 kg/m2, and/or waist circumference >=90 cm (male) or >=80 cm (female) during the 12-week study period.
Study NCT02181777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GRASP
Description: GRoup trAining for Social skills in Psychosis
Study NCT02181777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Treatment as usual
Study NCT04280250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volitional Help-Sheet
Description: Self-help sheet in order to form implementation intentions
Study NCT04280250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: Psychoeducational self-help sheet
Study NCT02289586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: invasive ventilation
Study NCT02289586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional bronchoscopy
Study NCT02289586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interventional bronchoscopy
Study NCT02289586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive ventilation
Study NCT02289586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sedation(dezocine and midazolam)
Study NCT02289586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia(midazolam, fentanyl，rocuronium，propofol and Remifentanil）
Study NCT00222612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced intensification
Description: Deletion of one 7 week treatment block containing dexamethasone, vincristine, doxorubicin, Peg-asparaginase, intrathecal methotrexate, cyclophosphamide, cytarabine.
Study NCT00222612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard childhood UK ALL protocol
Description: No additional treatment to standard protocol.
Study NCT00222612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensified treatment including Capizzi maintenance
Description: Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase
Study NCT02706977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Sinemet CR
Description: Sinemet CR (25 mg carbidopa/100 mg levodopa) will be taken by mouth twice daily for two weeks.
Study NCT02706977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Sinemet CR
Description: Sinemet CR (50 mg carbidopa/200 mg levodopa) will be taken by mouth twice daily for two weeks.
Study NCT02706977 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RETeval Electroretinogram (ERG) Testing
Description: ERG testing consists of sitting in the dark for 15 minutes. During the procedure, participants will have a single-use adhesive sensor strip placed on the skin near the eye. A hand-held device, called the RETeval, will be placed in front of the eye and a series of flashes and flickering lights presented. The light intensity level is typically not uncomfortable. When right eye imaging is complete, the procedure will be repeated on the left eye. Both eyes will be evaluated in less than 5 minutes for most participants. Electroretinogram (ERG) testing will be completed at baseline, day 1, week 2, and week 4.
Study NCT02706977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RETeval Electroretinogram (ERG) Testing
Description: ERG testing consists of sitting in the dark for 15 minutes. During the procedure, participants will have a single-use adhesive sensor strip placed on the skin near the eye. A hand-held device, called the RETeval, will be placed in front of the eye and a series of flashes and flickering lights presented. The light intensity level is typically not uncomfortable. When right eye imaging is complete, the procedure will be repeated on the left eye. Both eyes will be evaluated in less than 5 minutes for most participants. Electroretinogram (ERG) testing will be completed at baseline, day 1, week 2, and week 4.
Study NCT02706977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Contrast Sensitivity Testing
Description: Contrast sensitivity testing consists of looking at a series of moving lines on a tablet device. The lines will change from white to grey to black. Participants will be asked to determine when they can no longer distinguish between the lines. Contrast sensitivity testing will be completed at baseline, day 1, week 2, and week 4.
Study NCT02706977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast Sensitivity Testing
Description: Contrast sensitivity testing consists of looking at a series of moving lines on a tablet device. The lines will change from white to grey to black. Participants will be asked to determine when they can no longer distinguish between the lines. Contrast sensitivity testing will be completed at baseline, day 1, week 2, and week 4.
Study NCT02706977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Visual Acuity Testing
Description: Participants will be asked to look at an eye chart with letters or symbols that become smaller as they move from top to bottom of the chart. Visual acuity testing will be completed at baseline, day 1, week 2, and week 4.
Study NCT02706977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Acuity Testing
Description: Participants will be asked to look at an eye chart with letters or symbols that become smaller as they move from top to bottom of the chart. Visual acuity testing will be completed at baseline, day 1, week 2, and week 4.
Study NCT02902458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual interview with a qualified psychologist
Description: Individual, recorded interview with a qualified psychologist to discuss any and all subjects related to the ICD implantation, or any other topics deemed relevant by the patient.
Study NCT01801163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib x 2 weeks followed by Stereotactic Radiotherapy and then sorafenib until disease progression.
Study NCT01801163 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Sorafenib x 2 weeks followed by Stereotactic Radiotherapy then Sorafenib until disease progression.
Study NCT02271269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Value Pricing Subsidies
Description: * Usual care for glaucoma~* Subsidies granted to adherent patients for their glaucoma medications and physician visits, lowering the costs of treatment and providing a financial incentive for patients to take their medicines as prescribed.~* Subsidy (25 / 50%) granted based on meeting dose-rate adherence percentage targets (75 / 90%) at the month 3 and 6 assessment points.
Study NCT00828776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heparin sodic - Cristália
Description: 5000UI/mL
Study NCT00828776 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: heparin - Liquemine (Roche)
Description: 5000UI/mL
Study NCT03829228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proglucamune
Description: Following screening and enrollment, participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks. Each Proglucamune tablet contained \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
Study NCT03888443 — intervention group
Intervention type: DEVICE
Intervention: Bimanual 3D Motion Analysis  Be-API 
Description: Movements will be measured using an optoelectronic system (12 cameras) which captures the displacement of 26 markers placed on the upper limbs and trunk of the child, according to the standards of the International Society of Biomechanics.~The child is installed on a chair and table height (equipment adapted and approved for pediatrics). A game board is installed in front of the child, with objects to handle, set and placed according to its anthropometry (joystick, steering wheel, buzzer, board, chip).
Study NCT00207077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab + Erlotinib
Description: IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.
Study NCT04866784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Transcutaneous electrical nerve stimulation (TENS) is a non-pharmacologic intervention for acute and chronic pain. This treatment involves the application of electric current through the skin; it is safe, easy to use, and inexpensive